Gossamer Bio (NASDAQ:GOSS) Given "Buy" Rating at HC Wainwright

Gossamer Bio (NASDAQ:GOSS - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $10.00 price target on the stock.

GOSS has been the subject of several other research reports. Wedbush started coverage on Gossamer Bio in a research note on Friday, April 5th. They issued an "outperform" rating and a $4.00 price target for the company. Piper Sandler reissued an "overweight" rating and issued a $15.00 target price on shares of Gossamer Bio in a report on Wednesday, March 27th. Finally, The Goldman Sachs Group dropped their price objective on Gossamer Bio from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, March 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $7.65.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS traded up $0.04 during mid-day trading on Monday, reaching $0.78. The company's stock had a trading volume of 8,505,996 shares, compared to its average volume of 1,325,127. The stock has a fifty day moving average of $1.11 and a two-hundred day moving average of $0.93. Gossamer Bio has a 52 week low of $0.45 and a 52 week high of $1.88. The firm has a market capitalization of $176.61 million, a PE ratio of -0.55 and a beta of 1.84. The company has a debt-to-equity ratio of 3.14, a current ratio of 5.94 and a quick ratio of 5.94.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). As a group, sell-side analysts anticipate that Gossamer Bio will post -0.75 EPS for the current fiscal year.

Insider Activity

In other Gossamer Bio news, CEO Faheem Hasnain sold 23,172 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $1.16, for a total value of $26,879.52. Following the completion of the sale, the chief executive officer now owns 120,293 shares in the company, valued at approximately $139,539.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 33,620 shares of company stock worth $39,682 over the last three months. Corporate insiders own 9.50% of the company's stock.

Institutional Trading of Gossamer Bio

Several large investors have recently added to or reduced their stakes in the company. ARCH Venture Management LLC bought a new stake in Gossamer Bio during the 3rd quarter worth about $6,709,000. Silverarc Capital Management LLC bought a new position in Gossamer Bio during the third quarter worth $5,105,000. Monashee Investment Management LLC acquired a new stake in shares of Gossamer Bio during the third quarter worth $4,417,000. Armistice Capital LLC acquired a new stake in shares of Gossamer Bio during the third quarter worth $4,127,000. Finally, Stonepine Capital Management LLC acquired a new position in Gossamer Bio in the third quarter valued at about $2,781,000. 81.23% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.